Ampullary (Ampulla of Vater)

For questions about these or other cancer clinical trials, please contact our Cancer Research Navigator at 949-764-2704 or lauren.wagner@hoag.org.

(108-25) A Phase 1 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors

(110-25) Phase 1, Multicenter Trial of Subcutaneous Trastuzumab Deruxtecan in Participants with Metastatic Solid Tumors

(120-25) A Phase 1/2, Open-Label, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ETX-636, a Pan-Mutant-Selective PI3Kα Inhibitor, as Monotherapy and in Combination with Other Anticancer Therapies in Participants with Advanced Solid Tumors

(141-25) A phase I/II study of VLS-1488 (an oral KIF18A inhibitor) in subjects with advanced cancer

(142-25) A Phase 1, Multicenter, Open-Label, Dose Escalation, Dose Expansion and Dose Confirmation Study of BHV-1530 in Adult Participants with Advanced or Metastatic Solid Tumors

(146-22) LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor

(148-24) A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Subjects with Carcinoid Syndrome and Well-Differentiated Neuroendocrine Tumor

(167-25) A Phase Ia/Ib multicenter, open-label trial to evaluate safety, tolerability, and efficacy and dosimetry of LY4337713, a FAP-targeted radioligand therapy, in adults with FAP-positive advanced solid tumors

(169-24)The Effect of Pre operative Meditation Coaching on Adoption of Meditation Practice, Peri Operative pain, Distress and Medication Use (169-25) A Phase 1 Dose-Escalation Study of SLV-324 in Subjects with Metastatic Solid Tumors

(177-24) A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants with Advanced-Stage Tumors

(179-24) A Phase 1 Dose-Escalation Study of SLV-154 in Subjects with Metastatic Solid Tumors

(186-24) A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1419 in Participants with Advanced/Metastatic Solid Tumors

(188-24) Phase 1 study of ACR-2316 in subjects with advanced solid tumors

(232-24) A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors

(237-24) Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors

(240-24) Pilot study of characterization of hereditary cancer-associated germline variants with long-read sequencing (LRS)

(246-23) An open-label, multicenter, first-in-human Phase 1a/1b study to evaluate safety and tolerability of QXL138AM in participants with locally advanced unresectable and/or metastatic solid tumors and multiple myeloma

(248-24) A Phase 1b, 2-part, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical ([225Ac]Ac-AKY-1189) in Patients with Previously Treated Locally Advanced or Metastatic Solid Tumors

(266-24) A Phase 1b Dose Escalation Study of AV-380 in Combination with Standard of Care Chemotherapy in Metastatic Cancer Patients with Cachexia and Elevated GDF-15 Levels

(139-25) A Phase 1, Open-label, Multi-center Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Azenosertib and to Assess the Safety and Tolerability of Azenosertib in Subjects with Solid Tumors

(163-24) Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination with Standard of Care for Newly-Diagnosed Adult Glioblastoma

Certain clinical trials may not be listed on ClinicalTrials.gov.